Previous 10 | Next 10 |
What do drugs for weight loss, pulmonary hypertension, and irritable bowel syndrome all have in common? Not much -- except they are all offerings in which Arena Pharmaceuticals (NASDAQ: ARNA) has come close to the finish line over the past two decades, only to come up short. IMA...
In the largest US IPO of the year to date, Coupang upsized and priced above the upwardly revised range to raise $4.6 billion at a $62.9 billion market cap. Online gaming platform, Roblox, completed the year's first direct listing, opening 43% above its reference price and beginning tr...
Arena Pharmaceuticals (ARNA) announces topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab in participants with abdominal pain due to Irritable Bowel Syndrome ((IBS)).In the study, olorinab did no...
- Olorinab investigated in three doses, 10 mg, 25 mg, and 50 mg, for abdominal pain associated with IBS-C & IBS-D - Trial did not meet primary endpoint in broad study population - Moderate to severe pain population at 50 mg showed statistically significant, clinica...
Prometheus Biosciences has filed to raise $125 million in a U.S IPO. The firm is developing treatments for inflammatory bowel disease conditions. RXDX is in Phase 1 safety trials for its lead candidate for the treatment of ulcerative colitis and Crohn's disease. For further ...
Image source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA) Q4 2020 Earnings Call Feb 23, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Arena Pharmaceuticals Inc (ARNA) Q4 2020 Earnings Call Transcript...
Arena Pharmaceuticals, Inc. (ARNA) Q4 2020 Earnings Conference Call February 23, 2021, 04:30 PM ET Company Participants Patrick Malloy - Vice President, Investor Relations and Corporate Communications Amit Munshi - President and Chief Executive Officer Laurie Stelzer - Executive Vice Presiden...
Arena Pharmaceuticals (ARNA): Q4 GAAP EPS of -$2.10 misses by $0.27.Strong cash position of $1.1 billion as of December 31, 2020Press Release For further details see: Arena Pharmaceuticals EPS misses by $0.27
- Significant pipeline progress with potentially first- or best-in-class drug candidates - Strong cash position of $1.1 billion as of December 31, 2020 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2020 financial results and provide a corporate update on Tuesday, February 23, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via confer...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...